What one share of Immunovant holds
Immunovant, Inc. (“Immunovant,” “we” or the “Company”) is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Our focus is on developing IMVT-1402 (imeroprubart), a potentially best-in-class inhibitor of the neonatal fragment crystallizable receptor (“FcRn”), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (“IgG”) antibodies.
Immunovant’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$2.82 |
|---|---|
| Cash and investments | $3.87 |
| Book value | $3.57 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | — | −$1.29 | $0.00 | −$1.29 | — | $0.19 |
| 2020 | — | −$1.54 | $0.00 | −$1.24 | — | $1.72 |
| 2021 | — | −$1.22 | $0.00 | −$0.95 | — | $4.00 |
| 2022 | — | −$1.43 | $0.00 | −$0.97 | — | $4.03 |
| 2023 | — | −$1.71 | $0.00 | −$1.53 | — | $2.78 |
| 2024 | — | −$1.88 | $0.00 | −$1.55 | — | $4.24 |
| 2025 | — | −$2.73 | $0.01 | −$2.48 | — | $4.16 |
| 2026 | — | −$2.77 | $0.00 | −$2.23 | — | $4.18 |
Common questions about Immunovant
How much does one share of Immunovant earn?
Over the last 12 months, Immunovant lost $2.82 for each share.
Does Immunovant pay a dividend?
Immunovant didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Immunovant’s book value per share?
Immunovant’s book value is $3.57 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Immunovant have?
Each share of Immunovant has $3.87 of cash and investments, as of June 30, 2026.
Has Immunovant bought back shares?
Immunovant’s share count rose about 723% from 2019 to 2026. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.